A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
NCT06452329
·
clinicaltrials.gov ↗
COMPLETED
Status
260
Enrollment
INDUSTRY
Sponsor class
Conditions
Gastric Cancer
Gastroesophageal Junction Cancer
Interventions
DRUG:
Nivolumab
Sponsor
Bristol-Myers Squibb